A major review looked at data from over 6,300 patients with advanced or metastatic non-small cell lung cancer. These patients received either a combination of two immune checkpoint drugs or standard control treatments. The study aimed to see if using both drugs at once would help patients live longer and manage their disease better.
Patients who got the dual drug treatment lived significantly longer than those on control treatments. The data showed a clear benefit for the group receiving both types of immune therapy. This combination approach also helped stop the cancer from spreading or getting worse for a longer time compared to other options.
Doctors noted that the benefits of this dual treatment varied depending on specific patient subgroups. While the study did not report detailed safety data in this summary, the overall results suggest this method improves the outlook for people with this serious form of lung cancer.